Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro ... fact that Eli Lilly's weight loss pipeline is one of ...

Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.

“So my dad wants me to eat at the restaurant, and I’m, like, I’ve got to go where I can drink green juice.” Photos show Lady Gaga’s weight loss transformation over the years.